HDP-CDV as an alternative for treatment of human herpesvirus-6 infections

Journal of Clinical Virology

Volumn 56, Issue 2, 2013, Pages 175-176

  Bonnafous, Pascale ^a   Bogaert, Sofie ^a   Godet, Angélique N ^a   Agut, Henri ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; DNA POLYMERASE; FOSCARNET; GANCICLOVIR; VALGANCICLOVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; DNA VIRUS; DRUG BIOAVAILABILITY; DRUG SAFETY; HERPES SIMPLEX; HUMAN; HUMAN HERPESVIRUS 6; LETTER; NEPHROTOXICITY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIRUS REPLICATION; VIRUS STRAIN;

ANTIVIRAL AGENTS; CELL LINE; CYTOSINE; HERPESVIRUS 6, HUMAN; HUMANS; MICROBIAL SENSITIVITY TESTS; ORGANOPHOSPHONATES; ROSEOLOVIRUS INFECTIONS;

EID: 84872375549     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.11.006     Document Type: Letter

References (10)

1. Isegawa Y., Hara J., Amo K., Osugi Y., Takemoto M., Yamanishi K., et al. Human herpesvirus 6 ganciclovir-resistant strain with amino acid substitutions associated with the death of an allogeneic stem cell transplant recipient. J Clin Virol 2009, 44:15-19.
2. Manichanh C., Olivier-Aubron C., Lagarde J.P., Aubin J.T., Bossi P., Gautheret-Dejean A., et al. Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo. J Gen Virol 2001, 82:2767-2776.
3. Montoya J.G., Neely M.N., Gupta S., Lunn M.R., Loomis K.S., Pritchett J.C., et al. Antiviral therapy of two patients with chromosomally-integrated human herpesvirus-6A presenting with cognitive dysfunction. J Clin Virol 2012, 55:40-45.
4. Williams-Aziz S.L., Hartline C.B., Harden E.A., Daily S.L., Prichard M.N., Kushner N.L., et al. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob Agents Chemother 2005, 49:3724-3733.
5. Bonnafous P., Naesens L., Petrella S., Gautheret-Dejean A., Boutolleau D., Sougakoff W., et al. Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet. Antivir Ther 2007, 12:877-888.
6. Bonnafous P., Boutolleau D., Naesens L., Deback C., Gautheret-Dejean A., Agut H. Characterization of a cidofovir-resistant HHV-6 mutant obtained by in vitro selection. Antivir Res 2008, 77:237-240.
7. Mace M., Manichanh C., Bonnafous P., Precigout S., Boutolleau D., Gautheret-Dejean A., et al. Real-time PCR as a versatile tool for investigating the susceptibility of human herpesvirus 6 to antiviral agents. Antimicrob Agents Chemother 2003, 47:3021-3024.
8. Hostetler K.Y. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antivir Res 2009, 82:A84-A98.
9. Hostetler K.Y. Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate. Viruses 2010, 2:2213-2225.
10. Painter W., Robertson A., Trost L.C., Godkin S., Lampert B., Painter G. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother 2012, 56:2726-2734.